Compare Johnson & Johnson (JNJ) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Invesco Preferred ETF — how do they compare? Johnson & Johnson trades at $249.43 (market cap $598.96B), while Invesco Preferred ETF trades at $10.79. The key difference: Johnson & Johnson pays a 2.15% dividend while Invesco Preferred ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | PGX | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | — |
52-Week High | $267.24 | $11.87 |
52-Week Low | $164.36 | $10.81 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
PGX trades at $10.81, down 0.46% on the day, with a bearish technical outlook from moving averages and neutral oscillators. The stock shows uniform support and resistance at $11. Recent corporate actions include upcoming dividends of $0.06 and $0.05 scheduled for July and June 2026, respectively. Financial ratios such as P/E, P/S, and ROE are not provided, limiting fundamental assessment.
The outlook for PGX is cautious due to bearish technical signals and negative media sentiment highlighting poor returns and limited downside protection. Investment opportunities may arise from dividend income, but risks include market volatility and structural subordination issues. Investors should weigh the income potential against significant downside risks in volatile conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
